恩扎卢胺与阿比特龙治疗化疗初治mCRPC的真实世界生存比较
基于美国退伍军人健康管理局数据库的回顾性分析,纳入3174例化疗初治转移性去势抵抗性前列腺癌患者,比较恩扎卢胺与阿比特龙的生存结局。校正合并症后,恩扎卢胺组死亡风险降低16%(HR=0.84,95%CI 0.76-0.94,p=0.0012),仅一线治疗者HR=0.71(95%CI 0.62-0.82);交叉换药后两组死亡风险相当(HR=1.10,95%CI 0.89-1.35)。
要点
- 真实世界化疗初治mCRPC中,恩扎卢胺较阿比特龙与更长中位治疗时间相关(9.93 vs 8.47个月,p=0.0008)。
- 校正合并症后恩扎卢胺组死亡风险降低16%(HR=0.84,95%CI 0.76-0.94)。
- 仅一线治疗者恩扎卢胺组总生存优于阿比特龙组(HR=0.71,95%CI 0.62-0.82)。
核心结论
- 在VHA真实世界化疗初治mCRPC患者中,起始恩扎卢胺治疗较阿比特龙与改善的总生存相关。
研究设计与样本
- 回顾性分析VHA数据库(2014年4月1日至2018年3月31日),纳入化疗初治mCRPC患者N=3174(恩扎卢胺n=1229,阿比特龙n=1945)。
- 采用Kaplan-Meier分析和多因素Cox比例风险回归模型评估总生存治疗效应。
主要发现
- 恩扎卢胺组与阿比特龙组平均年龄分别为74岁和73岁,中位随访分别为18.27个月和19.07个月。
- 恩扎卢胺组中位治疗持续时间长于阿比特龙组(9.93 vs 8.47个月,p=0.0008)。
- 校正基线合并症后,恩扎卢胺组死亡风险降低16%(HR=0.84;95%CI 0.76-0.94;p=0.0012)。
- 仅一线治疗者中,恩扎卢胺组总生存优于阿比特龙组(HR=0.71;95%CI 0.62-0.82)。
- 交叉换药者中,恩扎卢胺换至阿比特龙与阿比特龙换至恩扎卢胺的死亡风险相当(HR=1.10;95%CI 0.89-1.35)。
临床怎么用
- 在化疗初治mCRPC的真实世界人群中,恩扎卢胺可作为与阿比特龙相比总生存更优的起始治疗选择之一。
- 对于仅接受一线治疗的患者,恩扎卢胺的总生存优势更为明显(HR=0.71)。
- 交叉换药后两组死亡风险相当,提示序贯治疗选择需结合患者具体情况。
局限性
- 为回顾性数据库分析,非随机对照设计,可能存在残余混杂。
- 研究基于VHA单支付方人群,外部推广性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluation of the comparative effectiveness of enzalutamide and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) is limited to meta-analyses of randomized trials that exclude patients with significant comorbidities. We evaluated overall survival (OS) in patients with chemotherapy-naive mCRPC treated with enzalutamide or abiraterone acetate (abiraterone) in a real-world single payer setting. METHODS: A retrospective analysis (4/1/2014-3/31/2018) of the Veterans Health Administration (VHA) database was conducted. Patients with mCRPC had ≥1 pharmacy claim for enzalutamide or abiraterone (first claim date = index date) following disease progression on surgical/medical castration, without chemotherapy <12 months prior to index date. Patients had continuous VHA enrollment for ≥12 months pre-index date and were followed until death, disenrollment, or end of study. Kaplan-Meier analysis and multivariable Cox proportional hazards regression models examined the OS treatment effect. RESULTS: Patients with chemotherapy-naive mCRPC (N = 3174; enzalutamide, n = 1229; abiraterone, n = 1945) had mean ages of 74 and 73 years, respectively. Median follow-up was 18.27 and 19.07 months with enzalutamide and abiraterone, respectively. Enzalutamide-treated patients had longer median treatment duration than abiraterone-treated patients (9.93 vs 8.47 months, respectively, p = 0.0008). After baseline comorbidity adjustment, enzalutamide-treated patients had a 16% reduced risk of death (hazard ratio [HR] = 0.84; 95% CI, 0.76-0.94; p = 0.0012). For patients who remained on first line-therapy only, enzalutamide-treated patients had improved OS versus abiraterone-treated patients (HR = 0.71; 95% CI, 0.62-0.82). Enzalutamide-treated patients who crossed over to abiraterone had a comparable risk of death versus abiraterone-treated patients who crossed over to enzalutamide (HR = 1.10; 95% CI, 0.89-1.35). These results were confirmed by sensitivity analysis, which considered prognostic variables. CONCLUSIONS: Retrospective analysis of the VHA database indicated that chemotherapy-naive patients with mCRPC initiating therapy with enzalutamide had improved survival versus abiraterone.
引用
- Tagawa ST, Ramaswamy K, Huang A, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021. PMID: 33612825. doi:10.1038/s41391-021-00318-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。